Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study

Table 4 Multivariate survival analysis in classical Hodgkin lymphoma patients

Variable	HIV- cHL		HIV- MC subtype		HIV- NS subtype
Variable	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)
Age ≥50 years	<0.001	6.837 (2.588-18.062)	0.009	15.669 (1.995-123.042)	0.915	0.888 (0.099-7.967)
Advanced stage	0.403	1.584 (0.539-4.652)	0.329	2.263 (0.440-11.654)	0.141	3.382 (0.669-17.095)
Bulky disease	0.040	3.822 (1.060-13.783)	0.051	5.146 (0.991-26.725)	0.646	1.732 (0.166-18.091)
Blood monocyte	0.111	0.906 (0.802-1.023)	0.100	0.860 (0.719-1.029)	0.009	0.640 (0.459-0.894)
IDO	0.111	1.018 (0.996-1.040)	0.378	1.011 (0.98601.037)	0.001	1.104 (1.043-1.168)
CD163	0.812	1.002 (0.982-1.023)	0.439	1.008 (0.987-1.030)	0.020	1.061 (1.009-1.116)
CD68	0.636	0.970 (0.854-1.101)	0.906	0.992 (0.872-1.129)	0.735	1.056 (0.772-1.443)

HR, hazard ratio; CI, confidential interval; HIV, human immunodeficiency virus; cHL, classical Hodgkin lymphoma; HR, hazard ratio; CI, confidential interval; IDO, indoleamine 2,3-dioxygenase.

ISSN: 1471-2407